

Localisation of archetype for Intractable disease surveillance program in Japan

Shinji KOBAYASHI

Agenda

- Archetype localisation
 - Localisation, internationalisation, adaptation
- Localisation to Japan
 - Intractable disease surveillance program
 - Archetype localisation/adaptation
- Summary

Ehime



Localisation / Internationalisation

- Localisation
 - Language translation
 - Currency, Date, time, time zone
 - Culture, rules, law
- Internationalisation
 - Capacity for multiple localisation

Common problems in localisation to Japan

- Translation
 - Word sequence
 - Ex. From A to B(En) AからBへ(Ja)
 - Dialog box
 - Not one to one
 - By context
- Character encoding
 - UTF-8, UTF-16, S-JIS, JIS, EUC-JPN....
- Address sequence
 - Reverse from Western style
 - Prefecture, City, Town, number

Archetype in intractable disease surveillance in Japan

- Localisation
 - Archetype translation to Japanese
 - Design for Japan domestic clinical issue
- Adaptation
 - General practice <-> Specialised medical service
 - Auto-immune disease, neuron degenerative disorders
 - Archetype adaptation to Japanese clinical environment
 - Easy: Physiology, Chemistry
 - Difficult: Demographics, Administrative concept

Why openEHR?

- Interoperability for
 - Clinical research
 - Healthcare governance
 - Evaluate clinical care
- ISO 13606 Standard
 - Experience
 - 20years
 - Establishment
 - Implementation

I Love this community!

Healthcare insurance in Japan

- Universal care
 - For all patient
 - For all medical provider
- Two system
 - Medical insurance(for all generation)
 - Long term care insurance(for aged people)
- Support program
 - Handicapped, Children, Single mother...

‘Nanbyo’

- So called ‘intractable disease’
- Definition
 - diseases that have resulted from an unidentifiable cause and, without a clearly established treatment, have a considerably high risk of disability
 - diseases that chronically develop and require a significant amount of labor for the patient’s care, causing a heavy burden on other family members of the patient, both financially and mentally

‘Tokutei shikkan’

- Specified rare and intractable disease
 - Public subsidized
- Definition
 - Chronic development and serious consequences
 - Treatment of these disease is expensive for patients and families.
 - Lack of information for diseases
- Classification
 - 56 diseases, 615,568 patients registered

List of 'tokutei shikkan'

01 Behcet disease
02 multiple sclerosis
03 myasthenia gravis 0
4 systemic lupus erythematosus (SLE)
05 subacute myelo-optico-neuropathy (SMON)
06 aplastic anemia
07 sarcoidosis
08 amyotrophic lateral sclerosis (ALS)
09 scleroderma , dermatomyositis, or polymyositis
10 idiopathic thrombocytopenic purpura
11 (1) polyarteritis nodosa (2) microscopic polyangiitis
12 ulcerative colitis
13 Takayasu arteritis
14 thromboangiitis obliterans, Buerger disease
15 pemphigus
16 spinocerebellar degeneration
17 Crohn disease
18 fulminant hepatitis
19 malignant rheumatoid arthritis (rheumatoid vasculitis)
20 Parkinson disease and related diseases -progressive supranuclear palsy - corticobasal degeneration -

Parkinson disease
21 amyloidosis
22 ossification of posterior longitudinal ligament (OPLL)
23 Huntington disease
24 moyamoya disease
25 Wegener granulomatosis
26 dilated cardiomyopathy, congestive cardiomyopathy
27 multiple system atrophy - striatonigral degeneration (SND)
-olivopontocerebellar atrophy (OPCA) -Shy-Drager syndrome
28 epidermolysis bullosa
29 pustular psoriasis
30 disseminated spinal canal stenosis
31 primary biliary cirrhosis
32 severe acute pancreatitis
33 idiopathic necrosis of the femoral head
34 mixed connective-tissue disease
35 primary immunodeficiency syndrome
36 idiopathic interstitial pneumonia
37 retinitis pigmentosa
38 prion diseases -Creutzfeldt-Jakob disease (CJD) - Gerstmann-Straussler-Sheinker syndrome -fatal

familial insomnia
39 primary pulmonary hypertension
40 neurofibromatosis type 1, neurofibromatosis type 2
41 subacute sclerosing panencephalitis (SSPE)
42 Budd-Chiari syndrome
43 idiopathic chronic pulmonary thromboembolism with pulmonary hypertension
44 lysosomal storage diseases - Fabry disease -other lysosomal storage diseases
45 adrenoleukodystrophy (ALD)
46 Familial Hypercholesterolemia (Homozygous type)
47 spinal muscular atrophy (SMA)
48 spinal and bulbar muscular atrophy (SBMA)
49 Chronic Inflammatory Demyelinating Polyneuropathy
50 Hypertrophic cardiomyopathy
51 Restrictive cardiomyopathy
52 Mitochondrial disease
53 lymphangioleiomyomatosis
54 Severe erythema multiforme (Acute Phase)
55 Ossification of the ligamentum flavum
56 Diencephalo-hypophysial dysfunction -Syndrome of

abnormal secretion of prolactin -Syndrome of abnormal secretion of gonadotropin -Syndrome of abnormal secretion of antidiuretic hormone - Syndrome of abnormal secretion of Thyroid stimulating hormone - Cushing disease - Acromegaly - Hypopituitarism

615,568 patients registered

The Specified Disease(tokutei shikkan) Treatment Research Program

- Prefecture government
 - Certificate and yearly renewal
 - Application document includes:
 - Application and consent form
 - Clinical research form certified by doctor
 - Certificate of residence, earnings, and other
- Subsidy
 - Partial-total by earnings

Problems

- Certificate criteria
 - Vary from prefecture to prefecture
- National data registry
 - Permitted researchers construct databases for their study at that time
 - Nation wide follow up system
 - Quality management
 - Epidemiological new findings
 - Security issues


Schedule

- First year (- March 2010)
 - Modeling a few clinical research forms
 - Ulcerative colitis, Crohn disease
 - Report the problems of existing forms
- Second year(April 2010 – March 2011)
 - Implementation of server and registry
 - More diseases modeling


Project organization

- Leader
 - Prof. Tsutomu Chiba, Gastroenterology, Kyoto Univ
- Clinical group
 - Prof. Tsuneyo Mitsumori, Clinical immunology, Kyoto Univ
 - Prof. Ryosuke Takahashi, Clinical neurology, Kyoto Univ
- Informatics Group
 - Prof Hiroyuki Yoshihara, Kyoto Univ
 - Eizen Kimura, Shinji KOBAYASHI, Prof Ken Ishihara, Ehime Univ


Mindmap designed for clinical research form, first trial




MindMap version 2



Mindmap version 3



MindMap current version




Archetype localisation/adaptation

- Address
- ESR/FBC
- Insurance
- Family history
- Severity?
- Modality?
- Terminology

Address in Nanbyo form

- Prefecture government
 - Nation budget
 - management by prefecture
 - Prefecture deal subsidy to patients
- Address archetype localisation
 - Lack of granularity for Japanese local government
 - Reversed style

FBC archetype




ESR/FBC

- ESR(Erythrocyte sedimentation ratio)
 - Marker for SLE activity(not CRP)
 - Included in FBC archetype
- FBC(Full blood Count)
 - WBC, RBC, Ht, Hb, Plt,(ESR)
 - WBC classification lacks immature myeloid series
- ESR is isolated from FBC
- WBC classification -> cluster?

Blood cell classification (microscopic)

- Myeloblast
- Promyelocyte
- Myelocyte
- Metamyelocyte
- Proerythroblast
- Basochromatic-
- Orthochromatic
- Normochromatic
- Megaloblast
- Erythroblast
- Reticulum
- Monoblast
- Promonocyte
- Phagocyte
- Lymphoblast
- Plasmacyte
- Megakaryocyte
- Promegakaryocyte

Health insurance(MML module)




Insurance

- Universality?
 - Public, private, conditions, country
 - Domestic matter?
- Admin entry?
 - Needs for billing procedure

Family History (cont.)


Family History for Budd-Chiari syndrome

- | | | |
|-----------------------|-----------------------------------|------|
| (1) Interfamily onset | 1.Yes (Relation:) | 2.No |
| (2) Collagen Disease | 1.Yes (Disease Name: /Relation:) | 2.No |
| (3) Blood disease | 1.Yes (Disease Name: /Relation:) | 2.No |
| (4) Venous thrombosis | 1.Yes (Disease Name: /Relation:) | 2.No |



- What model will be suitable for describing following family history?
- Other items
 - Marriage between relatives
 - Born in closed community


Family History Archetype



Severity

- Many criteria
 - TNM, CTCAE, MGFA, Yahr, UC, Chron
 - Grading?, Staging?
- Compatibility?
 - MG severity(MGFA) vs Parkinson severity(Yahr)
 - Non sense
 - CTCAE/NIH-CTC
 - Partially meaningful

Problem and diagnostic archetype



Modality

- Diagnostic imaging archetype
 - X-Ray, CT, MRI..
 - Detailed condition?
 - Vendor name, Serial No., kVp....
 - Procedure
 - Operation
 - Endoscopy

Terminology

- SNOMED-CT
 - For western countries?
 - Applicable in Asia, Africa?
- Free/Open/Libre terminology?
 - Wikipedia/SNS type terminology
 - Responsibility?

Summary

- Localisation
 - Demographics, Insurance
- For intractable disease
 - General practice <-> Specialised medical service
- Terminology
 - Assurance for Non SNOMED countries